Loading...
Loading...
HEPA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 4,458.3K |
| Operating I/L | -4,458.3K |
| Other Income/Expense | -407.7K |
| Interest Income | 0.0K |
| Pretax | -4,865.9K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -4,865.9K |
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of drug therapy treatments for chronic liver diseases. The company's primary focus is on the development of Rencofilstat, a cyclophilin inhibitor that targets multiple pathologic pathways involved in liver disease progression. Rencofilstat has completed Phase 2a clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and has shown potential in reducing liver fibrosis and hepatocellular carcinoma tumor burden in experimental NASH models. Additionally, the drug has demonstrated antiviral activities against hepatitis B, C, and D viruses through various mechanisms.
